![Jean Bennett](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jean Bennett
Directeur/Membre du Conseil chez
Retinal Degeneration Fund
Profil
Jean Bennett is the founder of Gensight Biologics SA (founded in 2012), Spark Therapeutics, Inc. (founded in 2013), Limelight Bio, Inc. (founded in 2017), and Opus Genetics, Inc. (founded in 2021).
She is currently the Director at Retinal Degeneration Fund since 2022.
Dr. Bennett holds a doctorate degree from Harvard University and the University of California, Berkeley.
Postes actifs de Jean Bennett
| Sociétés | Poste | Début |
|---|---|---|
Retinal Degeneration Fund
 Retinal Degeneration Fund Investment Trusts/Mutual FundsMiscellaneous Operates as a fund focuses on making mission-related investments in companies with projects nearing clinical testing | Directeur/Membre du Conseil | 21/07/2022 |
Anciens postes connus de Jean Bennett
| Sociétés | Poste | Fin |
|---|---|---|
Opus Genetics, Inc.
 Opus Genetics, Inc. BiotechnologyHealth Technology Provides clinical stage gene therapies for inherited retinal diseases | Fondateur | - |
| SPARK THERAPEUTICS, INC. | Fondateur | - |
Limelight Bio, Inc.
 Limelight Bio, Inc. BiotechnologyHealth Technology Develops genetic therapies | Fondateur | - |
| GENSIGHT BIOLOGICS S.A. | Fondateur | - |
Formation de Jean Bennett
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
9
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gensight Biologics SA
 Gensight Biologics SA Pharmaceuticals: MajorHealth Technology Manufactures and markets novel therapies for severe retinal neurodegenerative diseases | Health Technology |
Spark Therapeutics, Inc.
 Spark Therapeutics, Inc. BiotechnologyHealth Technology Develops therapy products for debilitating diseases | Health Technology |
Limelight Bio, Inc.
Limelight Bio, Inc. BiotechnologyHealth Technology Develops genetic therapies | Health Technology |
Retinal Degeneration Fund
Retinal Degeneration Fund Investment Trusts/Mutual FundsMiscellaneous Operates as a fund focuses on making mission-related investments in companies with projects nearing clinical testing | Miscellaneous |
Opus Genetics, Inc.
Opus Genetics, Inc. BiotechnologyHealth Technology Provides clinical stage gene therapies for inherited retinal diseases | Health Technology |
